BCS Wealth Management Makes New Investment in Pfizer Inc. (NYSE:PFE)

BCS Wealth Management acquired a new position in Pfizer Inc. (NYSE:PFE) during the 4th quarter, according to its most recent filing with the SEC. The fund acquired 45,715 shares of the biopharmaceutical company’s stock, valued at approximately $1,213,000.

Other institutional investors have also recently modified their holdings of the company. Sightline Wealth Advisors LLC grew its holdings in shares of Pfizer by 28.6% during the fourth quarter. Sightline Wealth Advisors LLC now owns 15,134 shares of the biopharmaceutical company’s stock worth $402,000 after buying an additional 3,366 shares in the last quarter. Pallas Capital Advisors LLC increased its holdings in shares of Pfizer by 487.5% during the 4th quarter. Pallas Capital Advisors LLC now owns 151,062 shares of the biopharmaceutical company’s stock worth $4,008,000 after buying an additional 125,351 shares during the last quarter. Miracle Mile Advisors LLC raised its holdings in shares of Pfizer by 11.2% in the 4th quarter. Miracle Mile Advisors LLC now owns 219,700 shares of the biopharmaceutical company’s stock worth $5,829,000 after purchasing an additional 22,097 shares during the period. Kwmg LLC lifted its position in Pfizer by 6.4% during the fourth quarter. Kwmg LLC now owns 173,153 shares of the biopharmaceutical company’s stock valued at $4,594,000 after buying an additional 10,344 shares in the last quarter. Finally, PPS&V Asset Management Consultants Inc. lifted its holdings in shares of Pfizer by 5.6% during the 4th quarter. PPS&V Asset Management Consultants Inc. now owns 15,201 shares of the biopharmaceutical company’s stock valued at $403,000 after acquiring an additional 807 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Pfizer news, Director Scott Gottlieb purchased 1,000 shares of Pfizer stock in a transaction on Wednesday, October 30th. The stock was bought at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the transaction, the director now owns 10,000 shares of the company’s stock, valued at $282,400. The trade was a 11.11 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 0.06% of the company’s stock.

Pfizer Trading Up 0.3 %

Shares of NYSE PFE opened at $26.79 on Tuesday. The company has a market cap of $151.82 billion, a price-to-earnings ratio of 36.20, a price-to-earnings-growth ratio of 0.63 and a beta of 0.64. The stock’s 50 day simple moving average is $26.16 and its 200 day simple moving average is $28.04. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. The business had revenue of $17.70 billion for the quarter, compared to analysts’ expectations of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The company’s revenue for the quarter was up 31.2% compared to the same quarter last year. During the same quarter last year, the company earned ($0.17) EPS. Equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.42%. The ex-dividend date is Friday, January 24th. This is a boost from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s payout ratio is 232.43%.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Bank of America restated a “neutral” rating and issued a $29.00 price target on shares of Pfizer in a report on Tuesday, December 10th. UBS Group dropped their target price on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 8th. Truist Financial reduced their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Wolfe Research began coverage on shares of Pfizer in a research report on Friday, November 15th. They set an “underperform” rating and a $25.00 price target for the company. Finally, Citigroup started coverage on shares of Pfizer in a research note on Friday, October 25th. They issued a “neutral” rating and a $30.00 price target for the company. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $32.00.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.